Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537843
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
Safety and Efficacy of Venetoclax Cytarabine and Metformin VenCM for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Safety and Efficacy of Venetoclax Cytarabine and Metformin VenCM for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia Multicenter Phase 2 Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VenCM
Brief Summary:
Phase 2 clinical trial to evaluate the combination of venetoclax cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia
Detailed Description:
Subjects will be included voluntarily after informed consent Diagnosis of AML in accordance with the WHO classification and determination of inegibility to induction therapy or refractory or relapsed disease after initial treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None